预约演示
Ferring begins bladder cancer gene therapy rollout through focused program
临床3期上市批准基因疗法
While Ferring is looking at several different models, manufacturing of the gene therapy Adstiladrin is expected to hit full capacity by 2025.
After Ferringg approval at the end of last year for a potential alternative to bladder rAdstiladrinertain bladder cancer patients, Ferring Pharmaceuticals has given the gene therapy Adstiladrin to its first commercial patient.
The patient, a 78-year-old man in the Midwest, is the first of many to receive treatment through Ferring’sbladder cancernce programFerring Pharmaceuticalsto ensure patients can accesAdstiladrinduring a major manufacturing scale-up.
Because the adenovirus vector-based therapy is complicated to make, the company knew it had to be “very, very responsible” to ensure it was getting the med to patients while ramping up manufacturing, Ferring’s chief scientific officer Elizabeth Garner, M.D., MPH, said in an interview.
Two new sites were cleared to specifically produce Adstiladrin earlier this summer, one in Finland and the other in New Jersey. Manufacturing should hit full capacity by 2025 when Ferring expects to rFerring$200 million in milestone payments from Royalty Pharma through a royalty deal worth up to $500 million.
For now, investigators who studied Adstiladrin in iAdstiladrintrial and community clinics with the highest number of eligible patients can participate in the early experience progrFerringRoyalty Pharma
More clinics will be invited to joiAdstiladrinam as manufacturing output increases. The program will continue to expand in the next year or so, Garner said.
Importantly, the framework makes sure that any patient dosed during the first round can come back for their entire treatment regimen of every three months stretched out over a minimum of one year, despite the tight supply. The recently treated patient scheduled his next appointment for December.
Adstiladrin was approved last December to treat high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer with carcinoma in situ (CIS) with or without papillary tumors. It’s the first gene therapy to target high-risk and non-muscle invasive bladder cancer in patients who no longer respond to standard therapy and is administered directly into the bladder from a catheter.
Adstiladrin was also enrolled in Ferring’s real-world evidence study, called ABLE-4(BCG)-unresponsive non-muscle invasive bladder cancercarcinoma in situ (CIS)papillary tumorshigh-risk and non-muscle invasive bladder cancer
Through the study, the company wiFerringyze data evaluating not only the drug’s effectiveness through measures such as durability, survival and complete response rates but also patient, caregiver and physician experience. Those outcomes will be determined through several questionnaires that can give the company a better picture of what the quality of life looks like for patients treated and the impact on their caregivers, Garner said.
ABLE-41 is expected to last up to two years.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。